{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269537","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.052110+00:00","generated_at":"2026-05-16T23:45:20.190701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alector Q3 net loss $34.7M; cash $291.1M; selects lead candidates AL137, AL050; RIF 47%","bullets":["Net loss $34.7M ($0.34/sh) vs $42.2M ($0.43) in Q3 2024; revenue $3.3M, down from $15.3M.","Cash $291.1M, with $20M ATM proceeds Sep-Oct 2025; runway through 2027.","Lead candidates selected: AL137 (ABC anti-amyloid beta, IND 2026) and AL050 (ABC GCase, IND 2027).","Latozinemab Phase 3 INFRONT-3 failed; open-label extension discontinued.","Implemented ~47% workforce reduction in Oct 2025 to focus on priority programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269537","json":"https://secwatch.observer/filing/0001193125-25-269537.json","markdown":"https://secwatch.observer/filing/0001193125-25-269537.md","text":"https://secwatch.observer/filing/0001193125-25-269537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000119312525269537/0001193125-25-269537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000119312525269537/alec-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:45:20.190701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}